April - 2019

MECFA Blog

How Organ Transplant Works

The misconception that all patients in need of organ donation are responsible for their ill health should not suffice. Of course, there...

Common virus could speed up cystic fibrosis

A new study has found that cytomegalovirus, which is normally dormant in people who have it, can become active again in people with...

Cytomegalovirus – an unrecognised potential contributor to cystic fibrosis disease progression?

Given increasing body of work supporting an association of cytomegalovirus (CMV) seropositivity with several chronic medical conditions,...

Large Sugar Molecule Disrupts B. cepacia Bacteria from CF Patients, Study Shows

An experimental large sugar molecule called poly (acetyl, arginyl) glucosamine, or PAAG, was able to disrupt treatment-resistant biofilms...

The Future of Cell and Gene Therapy

Each passing year, the success of cell and gene therapy (CGT) becomes clearer, more widely covered in the media, and is increasingly the...

Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibr

EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102...

Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine

LONDON, April 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical stage...

Choline Supplementation Improves Lung Function, Liver Health in CF Patients, Study Shows

Choline supplementation improves lung function and liver health in people with cystic fibrosis (CF), and should be considered as a...

Mucus and Inflammation, Rather Than Infections, are Early Drivers of Lung Disease in CF, Study Says

Early accumulation of abnormally thick mucus and inflammation in the lungs, rather than bacterial infections, may be the initial trigger...

Positive Expiratory Pressure (PEP)

Cystic fibrosis (CF) is a genetic condition caused by abnormalities in the function of the cystic fibrosis transmembrane regulator (CFTR)...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p